Zimmer Biomet Holdings Inc (ZBH)
117.30
+0.01
(+0.01%)
USD |
NYSE |
Dec 08, 16:00
117.30
0.00 (0.00%)
Pre-Market: 20:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 24.51B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -6.08% |
| Valuation | |
| PE Ratio | 51.90 |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 3.388 |
| Price to Book Value | 1.959 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | 0.24 |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.4536 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 49.73% |
Profile
| Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly two thirds of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, sports medicine, and related surgical products. The firm spun out its dental and spine businesses in 2022. |
| URL | https://www.zimmerbiomet.com |
| Investor Relations URL | https://investor.zimmerbiomet.com/ |
| HQ State/Province | Indiana |
| Sector | Healthcare |
| Industry | Medical Devices |
| Equity Style | Mid Cap/Blend |
| Next Earnings Release | Feb. 02, 2024 (est.) |
| Last Earnings Release | Nov. 07, 2023 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Sep. 28, 2023 |
Ratings
Profile
| Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly two thirds of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, sports medicine, and related surgical products. The firm spun out its dental and spine businesses in 2022. |
| URL | https://www.zimmerbiomet.com |
| Investor Relations URL | https://investor.zimmerbiomet.com/ |
| HQ State/Province | Indiana |
| Sector | Healthcare |
| Industry | Medical Devices |
| Equity Style | Mid Cap/Blend |
| Next Earnings Release | Feb. 02, 2024 (est.) |
| Last Earnings Release | Nov. 07, 2023 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Sep. 28, 2023 |